Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Theravance Biopharma, Inc.NASDAQ: TBPH

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables grows, but more slowly than its trailing trend

Q1 FY2026 accounts receivables of $79.95M rose 50.6% year over year, behind the +258.2% change in trailing-twelve-month accounts receivables. Sequentially, it fell 19.7% from the prior quarter. Over 3 fiscal years it compounded at +115.2% a year.

Context

  • Accounts receivables amounted to 25.2% of revenue in FY2025, up 23.7 pp from a year earlier.
  • Accounts receivables grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +50.6% toward the trailing-twelve-month pace of +258.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$79.95M-19.7% QoQ
Last fiscal yearDec 2025
-$27.1M+2705.3% YoY
LTMMar 2026
$176.65M+258.2% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.6%——
1 year+2705.3%——
3-year CAGR+115.2%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(27.1M) USD
Year-over-year change
-2705.3%

Accounts Receivables vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +258.2% is the highest of 6, against a peer median of +100.0%.
  • Accounts receivables amounts to 160.9% of revenue for TBPH, versus a peer median of 0.1%.
TBPH Competitors
Accounts Receivables for TBPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TBPHTheravance Biopharma, Inc.LTM Mar 2026$176.65M USD+258.2%+115.2%160.9%
GERNGeron CorporationLTM Mar 2026$9.92M USD-69.2%-35.1%5.1%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$1.23M USD+237.3%+3245.2%2.9%
REPLReplimune Group, Inc.LTM Dec 2025$354K USD-70.4%——
LENZLENZ Therapeutics, Inc.LTM Mar 2026$14K USD——0.1%
VIRVir Biotechnology, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
TYRATyra Biosciences, Inc.LTM Mar 2026$0 USD———
VALNValneva SELTM Mar 2026€0 EUR+100.0%+2.4%0.0%
Peer median (excluding TBPH) —+100.0%+2.4%0.1%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(265.07M)(92.82M)(55.19M)(56.42M)105.9M
Depreciation & Amortization8.6M7.02M4.26M3.62M5.64M
Deferred Income Tax003.21M(7.57M)(11.52M)
Stock-Based Compensation62.06M39.73M25.37M21.39M18.48M
Change in Working Capital(39.55M)42.35M(8.34M)20.36M120.47M
Accounts Receivables1.8M(2.72M)(689K)(966K)(27.1M)
Inventory00000
Accounts Payables(3.53M)(1.61M)6K750K326K
Other Working Capital(37.82M)46.68M(7.66M)20.57M147.24M
Other Non-Cash Items26.1M(183.28M)3.7M7.09M(423K)
Operating Cash Flow(207.86M)(186.99M)(27M)(11.54M)238.54M
Capital Expenditures(3.41M)(572K)(2.49M)(332K)(42K)
Acquisitions (Net)00000
Purchases of Investments(158.31M)(103.15M)(134.53M)(143.04M)(248.22M)
Sales of Investments286.2M158.02M102.81M155.65M142.98M
Other Investing Activities6K1.1B1.51M00
Investing Cash Flow124.49M1.15B(32.7M)12.28M(105.28M)
Debt Repayment(10.73M)(631.6M)000
Common Stock Issued108.18M0099K786K
Common Stock Repurchased(9.06M)(132.28M)(199.55M)(3.1M)(4.03M)
Dividends Paid00000
Other Financing Activities3.47M5.08M618K508K0
Financing Cash Flow91.86M(758.81M)(198.93M)(2.5M)(3.25M)
Effect of Forex Changes00000
Net Change in Cash8.5M208.21M(258.63M)(1.75M)130.01M
Free Cash Flow(211.26M)(187.56M)(29.49M)(11.87M)238.5M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.